Lv01
0 积分 2026-04-06 加入
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
5小时前
已完结
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
5小时前
已完结
Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes
6小时前
已完结
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
1个月前
已完结
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
1个月前
已完结
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
2个月前
已完结
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2个月前
已完结
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
2个月前
已完结
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
2个月前
已完结
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
2个月前
已完结
Immunotherapy resistance in colorectal cancer: therapeutic strategies and biomarker-guided approaches
皖公网安备34019202002308
